Recommended Dilution Buffer: Sterile PBS or 0.9% saline for reconstitution/dilution. It is recommended to use the reconstituted/diluted product within one month.
Formulation: 100 mM Pro-Ac，20 mM Arg，pH5.0
Endotoxin: < 0.001EU/μg, determined by LAL method.
Purity: >95%. Determined by SDS-PAGE
Purification: Purified, Protein A, affinity column
Storage: -80°C for 2 years under sterile conditions；
-20°C for 1 year under sterile conditions；
Avoid repeated freeze-thaw cycles.
Isotype: IgG1-Kappa
Adalimumab/阿达木单抗 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Mouse neutrophils
33-34 nM
1 minute
To evaluate the effect of adalimumab-TNFα immune complexes on reactive oxygen species (ROS) production in mouse neutrophils. Results showed that adalimumab-TNFα immune complexes significantly induced ROS production, whereas ozoralizumab-TNFα immune complexes did not.
Front Immunol. 2023 Apr 14;14:1149874
Mammary gland organoids
2 μg/ml
48 h
To evaluate the effect of Adalimumab on the multipotency of mammary basal cells, results showed that Adalimumab treatment promoted the differentiation of basal cells into luminal cells
Nature. 2020 Aug;584(7822):608-613
Adalimumab/阿达木单抗 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6J male mice
Immune complex-induced subcutaneous inflammation model
Intradermal injection
6.8 mM (1 mg/mL)
Single injection, observed for 4 hours
To evaluate the inflammatory response of adalimumab-TNFα immune complexes in a mouse subcutaneous inflammation model. Results showed that adalimumab-TNFα immune complexes significantly induced local inflammatory responses, including increased vascular permeability, edema, and neutrophil infiltration.
Front Immunol. 2023 Apr 14;14:1149874
BALB/c mice
Immunogenicity model
Subcutaneous injection
3 mg/kg
Weekly for 8 weeks
To evaluate the inhibitory effect of FA-conjugated adalimumab on ADA production, results showed FA-adalimumab significantly reduced anti-adalimumab antibody titers.
Acta Pharm Sin B. 2024 Feb;14(2):808-820
Tg197 transgenic mice
Rheumatoid arthritis model
Intraperitoneal injection
3 mg/kg
Twice weekly for seven weeks
To evaluate the efficacy of Adalimumab in a rheumatoid arthritis model. Results showed that Adalimumab significantly reduced arthritis symptoms and histological scores, but the bispecific antibody ADA-a2H showed superior efficacy at the same dose.
MAbs. 2012 Sep-Oct;4(5):600-13
Mice
Aged mouse model
Intraperitoneal injection
0.05 mg/kg
Every other day for 3 weeks
Anti-TNF therapy reduced the number of circulating Ly6Chigh monocytes and CCR2 expression levels, thereby improving anti-pneumococcal immunity in aged mice.
PLoS Pathog. 2016 Jan 14;12(1):e1005368
Mice
Not used
Intraperitoneal
20 mg/kg
Single dose
Adalimumab did not lower MAP nor attenuate in vitro myogenic vasoconstriction in mouse cremaster arteries
Nat Commun. 2017 Apr 5;8:14805
C57BL/6 and Notch1 antisense transgenic (NAS) mice
Collagen antibody-induced arthritis (CAIA) model
500 mg/kg
Single dose
To evaluate the effect of Adalimumab on the CAIA model. Results showed that Adalimumab significantly suppressed arthritis progression, reducing synovial inflammation, cartilage erosion, and neutrophil infiltration, with efficacy comparable to the γ-secretase inhibitor L-685,458.
Theranostics. 2018 Sep 9;8(17):4795-4804.
Mice
K5CreER/Rosa-tdTomato mammary gland model
Intraductal injection
0.15 mg
Single injection, observed for one week
To evaluate the effect of Adalimumab on the multipotency of mammary basal cells in vivo, results showed that Adalimumab treatment promoted the differentiation of basal cells into luminal cells
Nature. 2020 Aug;584(7822):608-613
Tg197 human TNF transgenic mice
Arthritis model
Subcutaneous injection
1 mg/kg
Twice weekly, from 3 weeks of age until 16 weeks of age
Evaluate the efficacy and immunogenicity of adalimumab during long-term administration, finding that 80% of mice developed anti-drug antibodies (ADAs)
搜索
